Skip to Main Content
Table 2

Log-transformed IGFBP7 at baseline and 1 year relative to subsequent outcomes in CANVAS

Baseline IGFBP7Baseline and 1-year IGFBP7
EventsHRadj (95% CI)*PC index with clinical covariates onlyC index with baseline IGFBP7 onlyC index with both (improvement from clinical covariates only)HRadj (95% CI)*PC index with clinical covariates onlyC index with both (improvement from clinical covariates only)
Sustained decline in eGFR by 40% 2.27 (1.05–4.93) 0.038 0.73 0.69 0.73 (0) 14.8 (7.2–30.6) <0.001 0.77 0.79 (+0.04) 
Progression to macroalbuminuria 2.50 (1.54–4.07) <0.001 0.81 0.63 0.81 (0) 3.80 (1.80–7.80) <0.001 0.66 0.81 (0.01) 
First progression of albuminuria 1.80 (1.36–2.38) <0.001 0.56 0.56 0.58 (+0.01) 1.76 (1.16–2.65) 0.007 0.56 0.57 (+0.01) 
Cardiovascular death 6.55 (3.93–10.9) <0.001 0.66 0.67 0.69 (+0.03) 2.69 (0.86–8.35) 0.09 0.65 0.68 (0) 
Renal composite 3.51 (1.66–7.42) 0.001 0.73 0.70 0.74 (+0.01) 15.7 (7.68–32.0) <0.001 0.77 0.80 (+0.04) 
Renal composite plus cardiovascular death 4.90 (3.16–7.60) <0.001 0.67 0.67 0.70 (+0.03) 6.90 (4.10–11.7) <0.001 0.68 0.71 (+0.01) 
Renal composite plus progression to macroalbuminuria 3.80 (2.50–4.07) <0.001 0.63 0.64 0.66 (+0.03) 7.40 (4.50–12.2) <0.001 0.68 0.69 (+0.02) 
Baseline IGFBP7Baseline and 1-year IGFBP7
EventsHRadj (95% CI)*PC index with clinical covariates onlyC index with baseline IGFBP7 onlyC index with both (improvement from clinical covariates only)HRadj (95% CI)*PC index with clinical covariates onlyC index with both (improvement from clinical covariates only)
Sustained decline in eGFR by 40% 2.27 (1.05–4.93) 0.038 0.73 0.69 0.73 (0) 14.8 (7.2–30.6) <0.001 0.77 0.79 (+0.04) 
Progression to macroalbuminuria 2.50 (1.54–4.07) <0.001 0.81 0.63 0.81 (0) 3.80 (1.80–7.80) <0.001 0.66 0.81 (0.01) 
First progression of albuminuria 1.80 (1.36–2.38) <0.001 0.56 0.56 0.58 (+0.01) 1.76 (1.16–2.65) 0.007 0.56 0.57 (+0.01) 
Cardiovascular death 6.55 (3.93–10.9) <0.001 0.66 0.67 0.69 (+0.03) 2.69 (0.86–8.35) 0.09 0.65 0.68 (0) 
Renal composite 3.51 (1.66–7.42) 0.001 0.73 0.70 0.74 (+0.01) 15.7 (7.68–32.0) <0.001 0.77 0.80 (+0.04) 
Renal composite plus cardiovascular death 4.90 (3.16–7.60) <0.001 0.67 0.67 0.70 (+0.03) 6.90 (4.10–11.7) <0.001 0.68 0.71 (+0.01) 
Renal composite plus progression to macroalbuminuria 3.80 (2.50–4.07) <0.001 0.63 0.64 0.66 (+0.03) 7.40 (4.50–12.2) <0.001 0.68 0.69 (+0.02) 

HRadj, adjusted HR.

*

Covariates for adjustment were selected using the Bayesian information criterion in patients randomized to placebo in the main study along with baseline IGFBP7 and treatment allocation. Improvement in the C index was changed above a base model of covariates excluding biomarker concentrations.

A 40% decrease in eGFR was sustained for two or more consecutive measures.

The renal composite end point from CANVAS comprised a 40% decrease in eGFR (sustained for two or more consecutive measures), the need for RRT (dialysis or transplantation), or renal death.

Close Modal

or Create an Account

Close Modal
Close Modal